Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InotivNOTVQ -26.00% Return-on-Tangible-Asset is -32.70% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Inotiv ranks worse than 69.48% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Inotiv's annualizedNet Income for the quarter that ended in Mar. 2026 was $-129.9 Mil. Inotiv's average total tangible assets for the quarter that ended in Mar. 2026 was $397.1 Mil. Therefore, Inotiv's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -32.70%.
The historical rank and industry rank for Inotiv's Return-on-Tangible-Asset or its related term are showing as below:
NOTVQ'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -95.62 Med: -12.66 Max: 7.3
Current: -21.09
During the past 13 years, Inotiv's highest Return-on-Tangible-Asset was 7.30%. The lowest was -95.62%. And the median was -12.66%.
NOTVQ's Return-on-Tangible-Asset is ranked worse than 69.48% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs NOTVQ: -21.09
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Inotiv Return-on-Tangible-Asset Related Terms
Inotiv Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Inotiv's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NOTVQ vs NSTM, PRPH, IDTA: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Inotiv's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Inotiv's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -32.70% mean?
Inotiv (NOTVQ) has a Return-on-Tangible-Asset of -32.70% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Inotiv and its competitors. According to the industry distribution chart, Inotiv ranks #148 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 69.5%.
Is Inotiv's Return-on-Tangible-Asset too high?
Inotiv's current Return-on-Tangible-Asset is -32.70%. Based on the distribution chart, Inotiv ranks #148 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Inotiv's Return-on-Tangible-Asset compare to NSTM and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #148 out of 213 companies for Return-on-Tangible-Asset. This places Inotiv in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Inotiv and its competitors. Inotiv's current Return-on-Tangible-Asset is -32.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.58, compared to a current price of $0.01 — trading 99.3% below its estimated fair value. The current Return-on-Tangible-Asset is -32.70%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Inotiv (NOTVQ), the current Return-on-Tangible-Asset is -32.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NOTVQ has been successfully added to your 
